Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last ¥2,581 JPY
Change Today +14.50 / 0.57%
Volume 2.3M
4568 On Other Exchanges
As of 1:00 AM 11/25/15 All times are local (Market data is delayed by at least 15 minutes).

daiichi sankyo co ltd (4568) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/6/15 - ¥2,756
52 Week Low
01/16/15 - ¥1,549
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for DAIICHI SANKYO CO LTD (4568)

Related News

No related news articles were found.

daiichi sankyo co ltd (4568) Related Businessweek News

No Related Businessweek News Found

daiichi sankyo co ltd (4568) Details

Daiichi Sankyo Company, Limited engages in the research, development, manufacture, import, sale, and marketing of pharmaceutical products in Japan and internationally. The company’s generic pharmaceuticals include olmesartan, azelnidipine, and amlodipine antihypertensive agents; loxoprofen, an anti-inflammatory analgesic; levofloxacin, a synthetic antibacterial agent; esomeprazole for ulcer treatment; memantine and donepezil for treating alzheimer’s disease; pravastatin and atorvastatin antihyperlipidemic agents; carvedilol for treating hypertension, angina pectoris, and chronic heart failure; iohexol to enhance visibility of diagnostic X-ray imaging; silodosin for treating dysuria; laninamivir for anti-influenza treatment; edoxaban, an anticoagulant; teneligliptin and pioglitazone type 2 diabetes mellitus inhibitors; denosumab for treating bone complications; denosumab for treating osteoporosis; and prasugrel, an antiplatelet agent. Its generic pharmaceuticals also comprise colesevelam for treating hypercholesterolemia and type 2 diabetes mellitus indication, as well as iron sucrose and ferric carboxymaltose injections for treating anemia. The company also provides over the counter products, such as Lulu, combination cold remedy; Daiichi Sankyo Ichoyaku, a multi-ingredient digestive remedy; Loxonin S, an antipyretic analgesic; Patecs, an antiphlogistic analgesic for external use; and Transino for treating melisma. In addition, it offers ActHIB, a haemophilus influenzae type b vaccine; Rotarix, a rotavirus vaccine; Influenza HA Vaccine; and Live Attenuated Measles/Rubella Combined Vaccine. Further, it manufactures and sells cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates, as well as pharmaceuticals and drugs for animals. Daiichi Sankyo Company, Limited was founded in 1899 and is headquartered in Tokyo, Japan.

Founded in 1899

daiichi sankyo co ltd (4568) Top Compensated Officers

Chief Executive Officer, President and Repres...
Total Annual Compensation: ¥123.0M
Compensation as of Fiscal Year 2015.

daiichi sankyo co ltd (4568) Key Developments

Daiichi Sankyo Company, Limited Doses First Subject in A Phase 1 Clinical Study for Lead Partnered Anticalin Program

Pieris Pharmaceuticals Inc. announced that collaborator Daiichi Sankyo Company, Limited dosed the first subject in a Phase I clinical study for the parties' lead partnered Anticalin program, also triggering an undisclosed milestone payment. The clinical trial is being conducted in the United States under an Investigational New Drug Application accepted by The U.S. Food and Drug Administration. Under the terms of the parties' 2011 collaboration research and technology licensing agreement, Pieris has received an upfront license fee, committed research funding, payments for research and development services and milestone payments. Pieris is eligible to receive additional preclinical milestone payments for the parties' second preclinical program, as well as development and commercial milestones for each program. The partnership could encompass for Pieris more than EUR 100 million per program in license fees, funding and milestones, not including royalties on sales of certain Anticalin proteins resulting from the collaboration. Daiichi Sankyo will have exclusive commercialization rights worldwide for all such products.

Daiichi Sankyo Company, Limited Announces Consolidated Earnings Results for the Second Quarter and Six Months Ended September 30, 2015; Revises Earnings Guidance for the Full Year of Ending March 31, 2016

Daiichi Sankyo Company, Limited announced consolidated earnings results for the second quarter and six months ended September 30, 2015. For the period, on consolidated basis, the company reported revenue of JPY 478,777 million against JPY 429,590 million a year ago. Operating profit was JPY 97,006 million against JPY 60,237 million a year ago. Profit before tax was JPY 90,801 million against JPY 62,163 million a year ago. Profit for the period was JPY 69,426 million against JPY 50,308 million a year ago. Profit attributable to owners of the company was JPY 70,696 million or JPY 101.69 diluted earnings per share against JPY 50,326 million or JPY 71.49 diluted earnings per share a year ago. Net cash flows from operating activities were JPY 60,884 million against JPY 56,753 million a year ago. Acquisitions of property, plant and equipment was JPY 15,908 million against JPY 17,063 million a year ago. Acquisition of intangible assets was JPY 27,648 million against JPY 21,400 million a year ago. For the second quarter, the company reported revenue of JPY 240.4 million against JPY 215.9 million a year ago. Operating profit was JPY 47.9 million against JPY 27.4 million a year ago. Profit before tax was JPY 45.6 million against JPY 29.5 million a year ago. Profit for the period was JPY 35.3 million against JPY 14.3 million a year ago. Profit attributable to owners of the company was JPY 35.8 million against JPY 15.1 million a year ago. The company revised earnings guidance for the full year of ending March 31, 2016. For the full year, the company expects revenue of JPY 980,000 million against JPY 950,000 million previously forecasted. Operating profit is expected to be JPY 120,000 million against JPY 120,000 million previously forecasted. Profit before tax is expected to be JPY 115,000 million against JPY 120,000 million previously forecasted. Profit attributable to owners of the company is expected to be JPY 75,000 million or JPY 109.75 basic earnings per share against JPY 75,000 million or JPY 108.12 basic earnings per share previously forecasted.

Daiichi Sankyo Company, Limited Announces Dividend for the Second Quarter of 2015, Payable on December 1, 2015; Provides Dividend Guidance for the Fiscal Year 2016

Daiichi Sankyo Company, Limited announced dividend of JPY 40.00 per share for the second quarter of 2015 compared to JPY 30.00 per share for the fiscal year 2014. The dividend is payable on December 1, 2015. The company provided dividend guidance for the fiscal year 2016. The company expects dividend for the fiscal year 2016 of JPY 30.00 per share.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4568:JP ¥2,580.50 JPY +14.50

4568 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioCryst Pharmaceuticals Inc $10.09 USD +0.06
BioMerieux €106.60 EUR -0.50
Exelixis Inc $5.44 USD -0.06
Infinity Pharmaceuticals Inc $8.69 USD +0.365
Ipsen SA €59.77 EUR +0.72
View Industry Companies

Industry Analysis


Industry Average

Valuation 4568 Industry Range
Price/Earnings 21.5x
Price/Sales 1.8x
Price/Book 1.4x
Price/Cash Flow 5.0x
TEV/Sales 0.8x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact DAIICHI SANKYO CO LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at